Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in Glioblastoma

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 331-346

  Bhat, Krishna P L ^a   Balasubramaniyan, Veerakumar ^b   Vaillant, Brian ^c   Ezhilarasan, Ravesanker ^a   Hummelink, Karlijn ^a   Hollingsworth, Faith ^a   Wani, Khalida ^a   Heathcock, Lindsey ^a   James, Johanna D ^a   Goodman, Lindsey D ^a   Conroy, Siobhan ^b   Long, Lihong ^a   Lelic, Nina ^d   Wang, Suzhen ^a   Gumin, Joy ^a   Raj, Divya ^b   Kodama, Yoshinori ^e   Raghunathan, Aditya ^f   Olar, Adriana ^a   Joshi, Kaushal ^g   Pelloski, Christopher E ^g   Heimberger, Amy ^a   Kim, SeHoon ^h   Cahill, Daniel P ^d   Rao, Ganesh ^a   DenDunnen, Wilfred F A ^b   Boddeke, Hendrikus W G M ^b   Phillips, Heidi S ⁱ   Nakano, Ichiro ^g   Lang, Frederick F ^a   Colman, Howard ^j   Sulman, Erik P ^a   Aldape, Kenneth ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Seton Brain and Spine Institute   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e OSAKA NATIONAL HOSPITAL   (Japan)

^f HENRY FORD HOSPITAL   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h Yonsei University College of Medicine   (South Korea)

ⁱ GENENTECH INC   (United States)

^j UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CD15 ANTIGEN; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; STAT3 PROTEIN; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA SPHERE CULTURE; HUMAN; HUMAN CELL; IONIZING RADIATION; MACROPHAGE; MESENCHYMAL STEM CELL; MICROGLIA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION RESPONSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84883656941     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.001     Document Type: Article

References (54)

1. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., Fumagalli M., Da Costa M., Brown C., Popov N., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
2. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
3. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
4. Bhat K.P., Salazar K.L., Balasubramaniyan V., Wani K., Heathcock L., Hollingsworth F., James J.D., Gumin J., Diefes K.L., Kim S.H., et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011, 25:2594-2609.
5. Bredel M., Bredel C., Juric D., Duran G.E., Yu R.X., Harsh G.R., Vogel H., Recht L.D., Scheck A.C., Sikic B.I. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J.Clin. Oncol. 2006, 24:274-287.
6. Bredel M., Scholtens D.M., Yadav A.K., Alvarez A.A., Renfrow J.J., Chandler J.P., Yu I.L., Carro M.S., Dai F., Tagge M.J., et al. NFKBIA deletion in glioblastomas. N.Engl. J. Med. 2011, 364:627-637.
7. Brescia P., Richichi C., Pelicci G. Current strategies for identification of glioma stem cells: adequate or unsatisfactory?. J.Oncol. 2012, 2012:376894.
8. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., Sulman E.P., Anne S.L., Doetsch F., Colman H., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
9. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
10. Chen J., McKay R.M., Parada L.F. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012, 149:36-47.
11. Chow L.M., Endersby R., Zhu X., Rankin S., Qu C., Zhang J., Broniscer A., Ellison D.W., Baker S.J. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011, 19:305-316.
12. Colman H., Zhang L., Sulman E.P., McDonald J.M., Shooshtari N.L., Rivera A., Popoff S., Nutt C.L., Louis D.N., Cairncross J.G., et al. A multigene predictor of outcome in glioblastoma. Neuro-oncol. 2010, 12:49-57.
13. Cooper L.A., Gutman D.A., Long Q., Johnson B.A., Cholleti S.R., Kurc T., Saltz J.H., Brat D.J., Moreno C.S. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE 2010, 5:e12548.
14. Cooper L.A., Gutman D.A., Chisolm C., Appin C., Kong J., Rong Y., Kurc T., Van Meir E.G., Saltz J.H., Moreno C.S., Brat D.J. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am. J. Pathol. 2012, 180:2108-2119.
15. Daginakatte G.C., Gutmann D.H. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum. Mol. Genet. 2007, 16:1098-1112.
16. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4:3.
17. Engler J.R., Robinson A.E., Smirnov I., Hodgson J.G., Berger M.S., Gupta N., James C.D., Molinaro A., Phillips J.J. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas. PLoS ONE 2012, 7:e43339.
18. Friedmann-Morvinski D., Bushong E.A., Ke E., Soda Y., Marumoto T., Singer O., Ellisman M.H., Verma I.M. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012, 338:1080-1084.
19. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
20. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
21. Gravendeel L.A., Kouwenhoven M.C., Gevaert O., de Rooi J.J., Stubbs A.P., Duijm J.E., Daemen A., Bleeker F.E., Bralten L.B., Kloosterhof N.K., et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009, 69:9065-9072.
22. Hayden M.S., Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
23. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N.Engl. J. Med. 2005, 352:997-1003.
24. Hjelmeland A.B., Wu Q., Wickman S., Eyler C., Heddleston J., Shi Q., Lathia J.D., Macswords J., Lee J., McLendon R.E., Rich J.N. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010, 8:e1000319.
25. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
26. Jamal M., Rath B.H., Tsang P.S., Camphausen K., Tofilon P.J. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia 2012, 14:150-158.
27. Jijiwa M., Demir H., Gupta S., Leung C., Joshi K., Orozco N., Huang T., Yildiz V.O., Shibahara I., de Jesus J.A., et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 2011, 6:e24217.
28. Koso H., Takeda H., Yew C.C., Ward J.M., Nariai N., Ueno K., Nagasaki M., Watanabe S., Rust A.G., Adams D.J., et al. Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc. Natl. Acad. Sci. USA 2012, 109:E2998-E3007.
29. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
30. Li W., Graeber M.B. The molecular profile of microglia under the influence of glioma. Neuro-oncol. 2012, 14:958-978.
31. Li B., Senbabaoglu Y., Peng W., Yang M.L., Xu J., Li J.Z. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification. Clin. Cancer Res. 2012, 18:5595-5605.
32. Liu C., Sage J.C., Miller M.R., Verhaak R.G., Hippenmeyer S., Vogel H., Foreman O., Bronson R.T., Nishiyama A., Luo L., Zong H. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011, 146:209-221.
33. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., Edwards C.R., Khanin R., Figueroa M.E., Melnick A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
34. Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
35. Magné N., Toillon R.A., Bottero V., Didelot C., Houtte P.V., Gérard J.P., Peyron J.F. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett. 2006, 231:158-168.
36. Markovic D.S., Vinnakota K., van Rooijen N., Kiwit J., Synowitz M., Glass R., Kettenmann H. Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression. Brain Behav. Immun. 2011, 25:624-628.
37. Mir S.E., De Witt Hamer P.C., Krawczyk P.M., Balaj L., Claes A., Niers J.M., Van Tilborg A.A., Zwinderman A.H., Geerts D., Kaspers G.J., et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010, 18:244-257.
38. Murat A., Migliavacca E., Hussain S.F., Heimberger A.B., Desbaillets I., Hamou M.F., Rüegg C., Stupp R., Delorenzi M., Hegi M.E. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS ONE 2009, 4:e5947.
39. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. Cancer Genome Atlas Research Network.
40. Park S., Hatanpaa K.J., Xie Y., Mickey B.E., Madden C.J., Raisanen J.M., Ramnarain D.B., Xiao G., Saha D., Boothman D.A., et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009, 69:2809-2816.
41. Pelloski C.E., Mahajan A., Maor M., Chang E.L., Woo S., Gilbert M., Colman H., Yang H., Ledoux A., Blair H., et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin. Cancer Res. 2005, 11:3326-3334.
42. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
43. Pietsch T., Wiestler O.D. Molecular neuropathology of astrocytic brain tumors. J.Neurooncol. 1997, 35:211-222.
44. Riddick G., Fine H.A. Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 2011, 7:439-450.
45. Sandberg R., Larsson O. Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics 2007, 8:48.
46. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
47. Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 2013, 110:4009-4014.
48. Stopschinski B.E., Beier C.P., Beier D. Glioblastoma cancer stem cells - From concept to clinical application. Cancer Lett. 2012, Published online June 2, 2012. 10.1016/j.canlet.2012.05.033.
49. Stricker S.H., Feber A., Engström P.G., Carén H., Kurian K.M., Takashima Y., Watts C., Way M., Dirks P., Bertone P., et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes Dev. 2013, 27:654-669.
50. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
51. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012, 483:479-483.
52. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. Cancer Genome Atlas Research Network.
53. Wu A., Wei J., Kong L.Y., Wang Y., Priebe W., Qiao W., Sawaya R., Heimberger A.B. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncol. 2010, 12:1113-1125.
54. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-267.